A single dose, placebo controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers

International Journal of Pharmaceutical Medicine

Volumn 11, Issue 2, 1997, Pages 65-70

  Wynne, Ronan D ^a   Braybrooke, Rebecca M ^a   Brown, Tanya ^a   Jones, Susan ^a   Stott, David A ^a   Thornton, Gillian M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antidepressive agents; Appetite depressants; Cardiovascular system; Clinical trials; Drug interaction; Obesity; Phase I

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATENOLOL; PLACEBO; SIBUTRAMINE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHONOCARDIOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC TIME INTERVAL;

EID: 0030770525     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sugrue MF. Neuropharmacology of drugs affecting food intake. Pharmacology and Therapeutics 1987;32:145-182.
2. Silverstone T. Appetite suppressants: a review. Drugs 1992; 43: 820-836.
3. Bucket WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Progress in Neuropsychopharmacology, Biology and Psychiatry 1988;12: 575-584.
4. Luscombe GP, Hopcroft RA, Thomas PC, Bucket WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989; 28: 129-134.
5. Luscombe GP, Slater NA, Lyons M, Wynne RD, Scheinbaum ML, Bucket WR. Effect of radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology 1990;100: 345-349.
6. Heal DJ, Frankland AJJ, Gosden J et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology 1992;107: 303-309.
7. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clinical Pharmacology and Therapeutics 1991; 50 (3): 330-337.
8. Bray GA, Blackburn GL, Ferguson JM et al. Sibutramine-dose-response and long-term efficacy in weight loss, a double-blind study. International Journal of Obesity 1994;18 (Suppl 2): 60.
9. Drouin P, Hanotin C, Courcier S, Leutenegger E. A dose-ranging study: efficacy and tolerability of sibutramine in weight loss. International Journal of Obesity 1994;18 (Suppl 2): 60.
10. Jones SP, Newman BM, Romananec FM. Sibutramine hydrochloride: weight loss in overweight subjects. International Journal of Obesity 1994;18 (Suppl 2): 61.
11. Halford JCG, Heal DJ, Blundell JE. Sibutramine suppresses food intake and preserves the behavioural sequence associated with satiety. Proceedings of pharmacologic treatment of obesity, satellite symposium of the 7th International Congress on Obesity, Saint-Adele, 1994; 45.
12. Connoley IP, Heal DJ, Stock MJ. The thermogenic effects of sibutramine. Proceedings of pharmacologic treatment of obesity, satellite symposium of the 7h International Congress on Obesity, Saint-Adele, 1994; 52.
13. Rasmussen EB, Kristjansen P. ECG changes during amitriptyline treatment. American Journal of Psychiatry 1963; 119: 781-782.
14. Vohra J, Burrows GD, Sloman JG. Assessment of cardiovascular side effects of therapeutic doses of tricyclic antidepressant drugs. Australian and New Zealand Journal of Medicine 1974; 5: 7-11.
15. Jefferson JW. A review of cardiovascular effects and toxicity of tricyclic antidepressants. Psychosomatic Medicine 1975; 37: 160-179.
16. Thorstrand C. Cardiovascular effect of poisoning with tricyclic antidepressants. Acta Medica Scandinavica 1974; 19S: 337-344.
17. Coull DC, Crooks J, Dingwall-Fordyce I, Scott A, Weir RD. Amitriptyline and cardiac disease. Risk of sudden death identified by monitoring system. Lancet 1970; ii: 590.
18. Moir DC, Crooks J, Cornwell WB et al. Cardiotoxicity of amitriptyline. Lancet 1972; ii: 561-564.
19. James TN, Isobe JH, Urthaler F. Analysis of components in a cardiogenic hypertensive chemoreflex. Circulation 1975; 52: 179-192.
20. Bigger JT, Giardina EGV, Kantor SJ, Glassman AH. Cardiac anti-arrhythmia effect of imipramine hydrochloride. New England Journal of Medicine 1977; 296: 206-210.
21. Anton AM, Sayre DF. A study of the factors affecting the aluminum oxidetrihydroxindole procedure for the analysis of catecholamines. Journal of Pharmacology and Experimental Therapeutics 1962; 138: 360-375.
22. Armitage P, Berry G. Statistical Methods in Medical Research, Second Edition, Blackwell, Oxford, 1987; 203-205.
23. Dunnett CW, Goldsmith C. When and how to do multiple comparisons. In: Buncher CR, Tsay J- Y, (eds.) Statistics in the Pharmaceuhcal Industry, Marcel Dekker, New York, 1981; 404.
24. Winer BJ. Statistical Principles in Experimental Design. Second Edition, McGraw Hill, New York, 1971; 796-809.
25. Burgress CD. Effects of antidepressants on cardiac function. Acta Psychiatrica Scandinavica 1981;63(Suppl290):370-379.
26. Cavero I, Gomeni R, Lefevre-Borg F, Roach AG. Comparison of mianserin with desipramine, maprotiline and phentolamine on cardiac presynaptic and vascular postsynaptic alpha-adrenoceptors and noradrenaline reuptake in pithed normotensive rats. British Journal of Pharmacology 1980; 68: 321-332.
27. Horn AS. The interaction of tricyclic antidepressants with the biogenic amine uptake systems in the central nervous system. Postgraduate Medical Journal 1976; S2, (Suppl 3): 25-30.